Menopur (Menotrophin)

Menotropin contains both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). After subcutaneous injection, it binds to FSH and LH receptors on ovarian cells, promoting follicular growth, estradiol synthesis, and final oocyte maturation, thereby facilitating ovulation and improving outcomes in assisted reproduction cycles.

The dose of Menopur is individualized and set by the prescribing clinician based on the patient’s ovarian reserve, treatment protocol and response to stimulation. Dosing may be adjusted during a cycle according to ultrasound and hormonal monitoring, and no fixed regimen is provided here.

Menopur is not indicated for use during an established pregnancy, and its safety in breastfeeding has not been established. It is generally avoided in pregnant or lactating women, and pregnancy testing is required before initiating therapy.

To order Menopur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

The primary alternatives to Menopur are recombinant FSH products such as follitropin alfa (Gonal‑F) or beta (Follitropin beta). Menopur provides both FSH and LH activity in a single preparation, which can reduce the need for separate LH supplementation, whereas recombinant products contain only FSH and may require an additional LH source for some protocols.

Menopur should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The powder should be reconstituted with the supplied diluent immediately before use, and any unused solution should be discarded according to local regulations.

Menopur is supplied as a sterile powder for solution for injection. After reconstitution with the appropriate diluent, it is administered by subcutaneous injection, typically in the abdominal wall or thigh, according to the dosing schedule determined by the treating specialist.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, abdominal pain, and respiratory distress; thromboembolic events such as deep‑vein thrombosis; and rare but potentially life‑threatening allergic reactions, including anaphylaxis.

Menopur should be avoided in women with confirmed pregnancy, uncontrolled thyroid disease, active hormone‑sensitive cancers, severe ovarian cysts, or those who have experienced severe OHSS in a previous cycle. Contra‑indications also include known hypersensitivity to menotropin or any component of the formulation.